Literature DB >> 24633406

Randomised, double-blind trial on the value of tapered discontinuation of clopidogrel maintenance therapy after drug-eluting stent implantation. Intracoronary Stenting and Antithrombotic Regimen: CAUTION in Discontinuing Clopidogrel Therapy--ISAR-CAUTION.

K Anette Fiedler, Julinda Mehilli, Sebastian Kufner, Anna Schlichting, Tareq Ibrahim, Dirk Sibbing, Ilka Ott, Heribert Schunkert, Karl-Ludwig Laugwitz, Adnan Kastrati, Stefanie Schulz1.   

Abstract

There is little evidence on the optimal mode of clopidogrel discontinuation. Epidemiological studies observed clustering of thrombotic events after cessation of chronic clopidogrel therapy. The underlying mechanism has been ascribed to transient platelet hyper-reactivity. Gradual tapering of clopidogrel may have the potential to attenuate this phenomenon. The objective of the present study was to assess whether in patients with drug-eluting stents (DES) gradual discontinuation of clopidogrel maintenance therapy is superior to conventional, abrupt discontinuation. Patients with planned discontinuation of chronic clopidogrel therapy after DES implantation were randomised in a double-blinded fashion to either gradual discontinuation (according to a tapering schema over four weeks) or abrupt discontinuation (after continued clopidogrel therapy for additional four weeks). The primary endpoint was the composite of cardiac death, myocardial infarction, stroke, stent thrombosis, major bleeding or rehospitalisation due to an acute coronary syndrome at 90 days. Enrollment of 3,000 patients was planned. The study was stopped prematurely due to slow recruitment after enrollment of 782 patients. At 90 days, nine of 392 patients (2.3%) with tapered cessation reached the primary endpoint compared to five of 390 patients (1.3%) with abrupt cessation (p=0.284). The composite of death or myocardial infarction occurred in three patients with tapered and three patients with abrupt discontinuation (p=0.764). In conclusion, tapered discontinuation of chronic clopidogrel therapy is not superior to abrupt discontinuation regarding the primary endpoint in this study. However, the results must be interpreted in view of the premature termination of the trial and low event rates.

Entities:  

Keywords:  Clopidogrel; drug-eluting stent; rebound; tapering

Mesh:

Substances:

Year:  2014        PMID: 24633406     DOI: 10.1160/TH13-11-0900

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  6 in total

1.  Gradual increase in thrombogenicity of juvenile platelets formed upon offset of prasugrel medication.

Authors:  Constance C F M J Baaten; Leo F Veenstra; Rick Wetzels; Johanna P van Geffen; Frauke Swieringa; Susanne M de Witt; Yvonne M C Henskens; Harry Crijns; Sven Nylander; J J J van Giezen; Johan W M Heemskerk; Paola E J van der Meijden
Journal:  Haematologica       Date:  2015-06-25       Impact factor: 9.941

2.  Dual antiplatelet therapy duration after the placement of a drug-eluting stent: what are the data?

Authors:  Jad Raffoul; Andrew J P Klein
Journal:  Curr Treat Options Cardiovasc Med       Date:  2015-03

Review 3.  Duration of Dual Antiplatelet Therapy in Coronary Artery Disease: a Review Article.

Authors:  Alex D Moseley; Fareed M Collado; Annabelle Santos Volgman; Gary L Schaer; R Jeffrey Snell
Journal:  Curr Atheroscler Rep       Date:  2016-07       Impact factor: 5.113

Review 4.  Optimal Duration of Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents: Shorter or Longer?

Authors:  Mineok Chang; Duk-Woo Park
Journal:  Cardiol Ther       Date:  2014-11-01

Review 5.  Stent thrombosis and restenosis: what have we learned and where are we going? The Andreas Grüntzig Lecture ESC 2014.

Authors:  Robert A Byrne; Michael Joner; Adnan Kastrati
Journal:  Eur Heart J       Date:  2015-09-28       Impact factor: 29.983

6.  Meta-analysis Comparing Outcomes of Type 2 Myocardial Infarction and Type 1 Myocardial Infarction With a Focus on Dual Antiplatelet Therapy.

Authors:  Christopher Reid; Ahmed Alturki; Andrew Yan; Derek So; Dennis Ko; Jean-Francois Tanguay; Amal Bessissow; Shamir Mehta; Shaun Goodman; Thao Huynh
Journal:  CJC Open       Date:  2020-02-24
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.